SGLT2 inhibitors and risk of genitourinary infections
This article examines the extent of these risks and how they may affect treatment adherence.
Source: Prescriber - Category: Primary Care Authors: Steve Chaplin Tags: Therapy Focus Source Type: research
More News: Canagliflozin | Dapagliflozin | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Forxiga | Invokana | Jardiance | SGLT2 Inhibitors | Urinary Tract Infections